Cross-agent recommendations, Novelty vs. Validation target discovery, AI-powered clinical progression prediction, bispecific antibody design, and faster, more accurate research reports platform-wide.
This release focuses on smarter research recommendations, deeper target-discovery scoring, a new bispecific antibody design capability, and a faster, more accurate reporting pipeline across every research agent.
New: Cross-Agent Recommendations
Every report can now suggest the right follow-up analysis automatically. After a Deep Research or Competitive Landscape report finishes, the platform reviews what was discussed and offers one-click hand-offs to Target Intelligence, Drug Repurposing, Competitive Landscape, Biomarker Discovery, or Hypothesis Generation — so you go from “interesting finding” to “next analysis” without re-typing context.
New: Smarter Target Discovery — Novelty vs. Validation
Target Intelligence can now rank candidate genes by how novel they are, not just how well-validated. A new Novelty vs. Validation chart plots every candidate on two axes — how under-explored a target is against how strong the causal evidence is — so you can find genuinely first-in-class opportunities instead of re-discovering the same well-known targets everyone else is already chasing. Candidate genes are now pulled from multiple independent sources (OpenTargets, DisGeNET, knowledge-graph mining, and literature/GWAS text-mining) and merged by consensus, broadening discovery beyond any single database’s blind spots.
New: AI-Powered Clinical Progression Prediction
Target Intelligence reports now include a machine-learning-based prediction of clinical progression likelihood for each candidate, alongside a single combined GO / CONDITIONAL-GO / NO-GO recommendation — a clear, defensible verdict instead of a wall of disconnected scores.
New: Bispecific Antibody Design
The Antibody Design agent (AADA) now supports bispecific antibody design across all 17 industry-standard formats, in addition to standard monoclonal design — expanding computational antibody discovery to dual-targeting therapeutics.
New: Interactive Visualizations in Research Reports
Deep Research, Competitive Landscape, and Biomarker Discovery reports now render interactive charts directly inline — knowledge-graph relationship diagrams, clinical trial landscape breakdowns, and predicted-vs-actual outcome timelines — so you can explore the underlying evidence visually instead of reading raw tables.
New: Floating Platform Assistant
A draggable, always-available chat assistant now floats over every page in the BioMedAI app. Ask it questions about any agent, any report, or the platform itself without losing your place in what you were doing.
Improved: Report Accuracy & Citations
We tightened citation handling across every research agent — Deep Research, Competitive Landscape, Biomarker Discovery, Drug Repurposing, and Pharmacovigilance now produce consistent, correctly formatted citations (author, journal, year) for both literature and clinical-trial sources. Clinical trial counts shown in charts now always match the trials listed in the accompanying table.
Improved: Faster, Streaming Reports
Biomarker Discovery, Competitive Landscape, Drug Repurposing, and Pharmacovigilance reports now stream their analysis live and run research steps in parallel, so you see meaningful progress section-by-section instead of waiting for the entire report to finish.
Improved: Hypothesis Generation for Any Disease
The Hypothesis Generation agent is no longer limited to a single disease area — it now works disease-agnostically across any biomedical topic, with deeper knowledge-graph-backed evidence.
Improved: Smoother Sessions & Navigation
Your login session now refreshes silently in the background, so you’re far less likely to be interrupted mid-task. The AI Tools sidebar has been reorganized for clarity, with new entries for Omics Intelligence and KO Intelligence, and faster gene-search autocomplete throughout.
And as always
We’ve continued hardening the platform’s infrastructure — deployment, security, and reliability improvements across every agent — so the product you depend on keeps getting steadier as it gets more capable.